Protective Role for the Disulfide Isomerase PDIA3 in Methamphetamine Neurotoxicity by Pendyala, Gurudutt et al.
Protective Role for the Disulfide Isomerase PDIA3 in
Methamphetamine Neurotoxicity
Gurudutt Pendyala
., Carly Ninemire
., Howard S. Fox*
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, United States of America
Abstract
Methamphetamine abuse continues to be a worldwide problem, damaging the individual user as well as society. Only
minimal information exists on molecular changes in the brain that result from methamphetamine administered in patterns
typical of human abusers. In order to investigate such changes, we examined the effect of methamphetamine on the
transcriptional profile in brains of monkeys. Gene expression profiling of caudate and hippocampus identified protein
disulfide isomerase family member A3 (PDIA3) to be significantly up-regulated in the animals treated with
methamphetamine as compared to saline treated control monkeys. Methamphetamine treatment of mice also increased
striatal PDIA3 expression. Treatment of primary striatal neurons with methamphetamine revealed an up-regulation of
PDIA3, showing a direct effect of methamphetamine on neurons to increase PDIA3. In vitro studies using a neuroblastoma
cell line demonstrated that PDIA3 expression protects against methamphetamine-induced cell toxicity and methamphet-
amine-induced intracellular reactive oxygen species production, revealing a neuroprotective role for PDIA3. The current
study implicates PDIA3 to be an important cellular neuroprotective mechanism against a toxic drug, and as a potential
target for therapeutic investigations.
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Introduction
Methamphetamine (METH) is a derivative of amphetamine
with increased central nervous system (CNS) potency. METH
abuse continues to ravage the US as well as countries around the
world. While taken for its effects on the CNS, METH has
significant neurotoxic properties. Several cellular and molecular
mechanisms are linked to METH associated neurotoxicity such as
oxidative stress, DNA damage, excitotoxicity, disruption of the
blood brain barrier, and microglial activation (reviewed by [1,2]).
While many of these effects have been described in rodents, a
number of studies on METH have been performed in monkeys
analyzing its toxic effects on brain monoamine dopamine (DA)
and serotonin (5-HT) neurons, focusing on the end-effects in the
striatum [3,4,5,6] with similar findings found in humans [7,8].
However in addition to damage to the termini of projecting
neurons, it is clear that METH also has toxic effects on various
non-DA/5-HT neurons present in the striatum and elsewhere [9].
Since METH is a significant co-morbid contributor in human
immunodeficiency virus (HIV) infection throughout the world
[10], we had previously performed a study on simian immuno-
deficiency virus (SIV) infected rhesus monkeys, comparing a
number of viral and immune parameters in those receiving
METH to those receiving control vehicle injections [11]. Because
these animals only differed in one factor, the administration of
METH, we utilized brain samples from these animals to perform
expression profiling in order to gain insights into the effects of
METH on the brain. The caudate and hippocampus were chosen
as they are affected by METH, both through monoaminergic
connections as well as being direct targets of METH neurotoxicity.
We identified the mRNA for PDIA3 (also called glucose regulated
protein 58, GRP58; and endoplasmic reticulum resident protein
57, ERp57) to be up-regulated in the animals treated with METH
as compared to the levels found in control monkeys treated with
the vehicle (phosphate buffered saline, PBS). Studies were then
performed to ascertain the role of PDIA3 in METH-induced
neurotoxicity.
Materials and Methods
Ethics statement
Materials used in these studies were from non-human primate
and mouse work performed under IACUC approval (from Scripps
Research Institute, 07-0067; University of Nebraska Medical
Center, 08-071-EP). Animal welfare was maintained by following
NIH (Public Health Service, Office of Laboratory Animal Welfare)
and USDA guidelines by trained veterinary staff and researchers
under Association for Assessment and Accreditation of Laboratory
Animal Care certification, insuring standards for housing, health
care, nutrition, environmental enrichment and psychological well-
being. These met or exceeded those set forth in the Guide for the
Care and User of Laboratory Animals from the National Research
Council of the US National Academy of Sciences. All efforts were
made to ameliorate suffering of animals, including use of
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human primate necropsy, and isoflurane at mouse sacrifice.
Rhesus macaques, SIV infection and METH treatment
As described previously [11], six rhesus monkeys (Macaca
mulatta) were infected with an in vivo serial passage derivative of
SIVmac251 [12,13]. At 19 weeks of infection, animals were
matched for viral load, and three were treated with an escalating
dose regimen of METH injected intramuscularly (5 week ramp-up
to 25 mg/kg/week), METH was maintained at this level for
another 18 weeks, mimicking a usage pattern in human chronic
METH abusers. The other three monkeys received PBS injections
on the same schedule. All animals were sacrificed at 42 weeks post
infection, before the development of AIDS.
Monkey necropsy and RNA isolation
For necropsy, animals were lethally anesthetized, intracardially
perfused with sterile PBS containing 1 U/ml heparin to clear
blood-borne cells from the brain, and vital organs removed for
pathological and other studies. Both caudate and hippocampus
were dissected from brains and snap frozen.
Mouse METH treatment
Eight week old C57BL/6J male mice (Jackson Laboratory, Bar
Harbor, ME) were subcutaneously injected with 10 mg/kg
METH or saline. Mice were sacrificed by isoflurane overdose at
30, 60, 120, and 240 minutes post injection. The striatum was
dissected and snap frozen in liquid nitrogen.
RNA isolation
RNA was isolated using Trizol (Life Technologies, Carlsbad,
CA) and quantified. spectrophotometrically.
Microarray
Microarray analysis was performed using rhesus gene chips
(Affymetrix, Santa Clara, CA). Briefly, 200 ng total RNA from
caudate was reverse-transcribed to generate cDNA followed by in
vitro transcription to generate biotinylated cRNA using the
Affymetrix 39IVT Express kit per manufacturer’s recommenda-
tions. Biotin labeled target was hybridized for 16 hrs to rhesus
arrays following standardized protocols per Affymetrix recom-
mendations. Following hybridization, arrays were washed, stained,
and scanned using the Affymetrix GeneChip System. Arrays were
evaluated for quality control (QC) by a variety of metrics including
background signal, 3959 ratios of actin and hybridization kinetics
of spike-in probes per Affymetrix recommended parameters. All
arrays passed QC and were subjected to further analysis. Data
were analyzed using the Partek Genomics Suite (Partek, St. Louis,
MO), and probe sets mapped to genes using the Database for
Annotation, Visualization and Integrated Discovery (DAVID v6.7)
[14]. Annotations were updated from the NCBI Gene database as
of 10/16/2011. MIAME compliant microarray data have been
deposited in the NCBI GEO database under accession GSE33707.
Quantitative real-time PCR
Isolated RNA was used for reverse transcription. In brief,
reverse transcription was carried out using the Superscript kit (Life
Technologies) at 2 mg RNA per 50 ml reaction, for 1 h at 42uC,
followed by 70uC for 5 min to inactivate the enzyme. RNase H
(New England Biolabs, Beverly, MA) treatment was then
performed at 37uC for 20 min. Then an equal volume of RNAse
and DNAse free water was added to each reaction.
Table 1. List of genes up-regulated in both the caudate and hippocampus from SIV infected, METH and PBS administered
monkeys.
Gene Symbol Gene Name Caudate Hippocampus
Fold p value Fold p value
FGF12 fibroblast growth factor 12 2.11 0.0058 2.11 0.0045
GLG1 golgi glycoprotein 1 2.41 0.0014 2.18 0.0027
LOC702990 microtubule-associated tumor suppressor 1 homolog 2.89 0.0054 2.67 0.0004
LOC715864 CUGBP Elav-like family member 4-like 2.46 0.0067 2.46 0.0041
OAZ2 ornithine decarboxylase antizyme 2 2.58 0.0002 2.12 0.0019
PDIA3 protein disulfide isomerase family A, member 3 4.92 0.0057 2.42 0.0056
PRKX protein kinase, X-linked 2.99 0.0074 2.09 0.0000
TBL1X transducin (beta)-like 1X-linked 2.09 0.0030 2.68 0.0004
TMBIM1 transmembrane BAX inhibitor motif containing 1 3.67 0.0029 2.25 0.0001
TST thiosulfate sulfurtransferase 2.63 0.0012 2.39 0.0053
The gene symbol, gene name, p-value (unpaired Student’s t-test) and fold change between the groups is indicated. Genes with p,0.01 and a fold change of .2 in both
regions are shown.
doi:10.1371/journal.pone.0038909.t001
Figure 1. PDIA3 is increased in by METH in monkeys in vivo.
Levels of PDIA3 mRNA expression from qRTPCR in brain regions from
the two groups of animals, differing only by METH treatment. (A)
caudate and (B) hippocampus. **p,0.01, unpaired Student’s t-test.
doi:10.1371/journal.pone.0038909.g001
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gene-specific primers and probes. Primers and probe sequences
were designed for rhesus using the Genescript online tool (https://
www.genescript.com/ssi-bin/app/primer) obtained from Euro-
gentec (San Diego, CA). Primer and probe sequences for PDIA3
are: Forward-TTGCACTGCCAACACTAACA, Reverse-
CTTCTTCAGGTGGCTGACAA, Probe-ACGGCGTCAGTG-
GATATCCAACC; for the housekeeping genes (18S, GAPDH
and TBP) sequences are given in [15]. For the human and mouse
PDIA3 and mouse HSPA5 genes, gene and species-specific
TaqMan primers and probes (Life Technologies) were used. The
above housekeeping genes for 18S and GAPDH were used since
they recognized human and mouse sequences as well. For
qRTPCR, in brief, 2 mL (1:100 diluted) cDNA was used for
assaying endogenous 18S ribosomal RNA; 5 mL (undiluted) each
for all other genes. All reactions were performed in duplicate.
12.5 mL of platinum qPCR UDG Supermix (Life Technologies)
was added per 25 ml reaction. The reaction mixture was brought
to a final concentration of 5 mM MgCl2. Real time PCR was
performed in 96-well plate on a Step One Plus machine (Life
Technologies). The delta Ct method was performed to determine
relative concentrations using housekeeping genes as the normal-
izing value. Unpaired student’s t-tests, or one-way ANOVA
followed by Tukey’s test, were used for statistical analysis.
Cell culture
Rat striatal neurons from embryonic day 18 Sprague Dawley
rat (Brain Bits LLC, Springfield, IL) were plated at a density of
4610
5 cells per well onto a 6-well plate containing two coverslips
per well in Neurobasal media containing B27 (Life Technologies).
After 8 days in vitro (DIV), cells were treated with 250 mM METH
for 24 h while control cells received no METH. The METH
Figure 2. PDIA3 is increased by METH in rodents in vivo. Time course of gene expression, determined by qRTPCR, in striatum from mice
treated with 10 mg/kg METH at the indicated time points. (A) PDIA3 (B) HSPA5 (as a positive control). *p,0.05 as determined by a one-way ANOVA
followed by a post hoc Tukey’s test.
doi:10.1371/journal.pone.0038909.g002
Figure 3. METH induction of PDIA3 in vitro in rodent neurons. Primary rat striatal neurons (8 DIV) stained for levels and distribution of PDIA3
after 250 mM METH treatment for 24 h along with MAP2 staining for neuronal structure and DAPI for cell nucleus. Control cells show basal levels of
PDIA3 while cells treated with METH show an increase and redistribution of PDIA3 along the neuronal processes indicated by arrowheads. Scale
bar=10 mm.
doi:10.1371/journal.pone.0038909.g003
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appropriate concentration on primary neurons without causing
excessive death and thus allowing measurement of protein
changes. After 24 h, cells were fixed in 4% paraformaldehyde
and double labeling performed as described below.
Human neuroblastoma cell line SK-N-BE(2), was cultured in
Dulbecco’s modified Eagle’s medium containing F12 supplement,
10% goat serum and GlutaMAX
TM-1. PDIA3 cDNA (Origene
Technologies, Rockville, MD) was cloned into pcDNA 3.2/V5
(Invitrogen). For overexpression, plasmid DNA transfection was
performed using Nucleofection (Lonza, Walkersville, MD) and
Geneticin-resistant cells selected. For generating knockdown
clones, PDIA3-specific GIPZ lentiviral shRNAmir was purchased
from ThermoScientific (Huntsville, AL). Following lentiviral
transduction puromycin-resistant cells were selected.
Cell toxicity assay
SK-N-BE(2) cells plated at a density of 5610
4 per well in a 24-
well plate were treated with 500 mM METH for 48 hours. Again
the METH concentration and time course was determined to be
appropriate for this cell line without causing excessive death, yet
able to produce a measurable effect. Cell toxicity was determined
by measuring lactate dehydrogenase (LDH) release from treated
cells using the LDH assay kit (Roche, Indianapolis, IN) as per the
manufacturer’s instructions. In brief, the culture medium from
cells was added to the enzymatic reaction buffer and incubated for
30 min at room temperature. Absorption values at 490 nm were
measured using a plate reader to determine levels of released
LDH. Culture medium from cells treated with 2% Triton-X 100
was used as a positive control.
Immunofluorescence
Double labeling was performed on both the control and METH
treated rat striatal neurons. Cells were permeabilized with 0.25%
Tween-20 in PBS for 20 min at room temperature and washed
twice with PBS. Cells were incubated in 10% normal goat serum
with 0.25% Tween-20 in PBS for 30 min at room temperature
and then incubated with anti-PDIA3 (1:100, Assay Designs,
Plymouth Meeting, PA) at 4uC overnight. After incubation with
fluorescence-labeled secondary antibody (1:100, goat anti-rabbit
IgG, Invitrogen) for 1 h at room temperature, the second primary
antibody anti-MAP2 (1:500, Sternberger Monoclonals, Luther-
ville, MD) was added at 4uC overnight. After incubation with
second secondary antibody (1:100, chicken anti-mouse IgG, Life
Technologies), cells were washed and mounted with Prolong Gold
with DAPI and analyzed by microscopy (Carl Zeiss, Thornwood,
NY).
For immunoflourescent labeling on parental, siRNA and
overexpression clones of SK-N-BE(2) cells, cells were permeabi-
lized with 0.25% Tween-20 in PBS for 20 min at room
temperature and washed twice with PBS. Cells were incubated
in 10% normal goat serum with 0.25% Tween-20 in PBS for
30 min at room temperature and then incubated with anti-PDIA3
(1:100, Assay Designs) at 4uC overnight. After incubation with
secondary antibody (1:100, goat anti-rabbit IgG, Invitrogen) for
1 h at room temperature, cells were mounted with Prolong Gold
with DAPI and analyzed by microscopy (Carl Zeiss).
Western Blot Analysis
Cells were harvested using ice cold PBS, pelleted, and lysed in
radioimmunoprecipitation assay buffer (ThermoScientific) with
16 protease inhibitors (Roche). Samples were sonicated and
measured for protein concentrations with the bicinchoninic acid
assay (ThermoScientific). 10 mg of protein was loaded into a 4–
12% BisTris gel (Invitrogen), electrophoresed, and transferred to a
nitrocellulose membrane (Invitrogen) using iBlot (Invitrogen).
Membrane was incubated in SuperBlock (ThermoScientific) for
1 hour at room temperature and then overnight in anti-PDIA3
(1:1000 Assay Designs) or anti-Actin (1:7500 Sigma-Aldrich, St.
Louis, MO) at 4uC. Membrane was washed three times with 16
Tris-buffered saline and 0.1% Tween-20 followed by incubation
with secondary antibody (1:10000 Anti-rabbit HRP, Thermo-
Scientific) for 1 hour at room temperature. Membrane was
washed as above and incubated for five minutes in 1:1 West Pico
chemiluminescent substrate (ThermoScientific) and the signal was
detected and quantified using Gel Logic Imaging System (Care-
stream, Woodbridge, CT).
Reactive oxygen species (ROS) assay
Intracellular production of ROS was assessed by 29,79-
dichlorfluorescein diacetate (DCFH-DA) oxidation. Clones over
Figure 4. Increased PDIA3 protects from METH toxicity.
Examination of SK-N-BE(2) cells for expression and knockdown for
PDIA3 by (A) western blot and (B) immunofluorescence. Scale
bar=10 mm. (C) Increased METH cytotoxicity in PDIA3 knockdown cells
compared to the PDIA3 expressors. Cytotoxicity was assessed by a
lactate dehyrogenase assay following 48 hrs exposure to 500 mM METH.
***p,0.001, unpaired Student’s t-test.
doi:10.1371/journal.pone.0038909.g004
Figure 5. Increased PDIA3 suppresses ROS production. Cells
treated with 500 mM METH for 1 h were assessed for production of ROS
using DCFH-DA assay. A significant increase in ROS production is seen
in cells knocked down for PDIA3, compared to PDIA3 expressors, both
with and without METH treatment. Two-way ANOVA p,0.0001,
Bonferroni post-tests. ***p,0.001. U – No treatment; M – METH
treatment.
doi:10.1371/journal.pone.0038909.g005
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cells were treated with 500 mM METH for 1 h and then incubated
with 20 mM DCFH-DA (Sigma) for 30 min. After incubation cells
were washed with PBS and the fluorescence visualized at 495 nm
for excitation and 529 nm for emission using a fluorescence plate
reader.
Statistics
All data represented were analyzed from three independent
experiments. Group comparisons were performed using the tests
described in the text and figure legends. Differences were
considered significant at p,0.05. Tests were performed using
Excel (Microsoft Corporation, Redmond, WA) and Prism software
(GraphPad Software Inc., San Diego, CA) for Macintosh.
Results
We initiated our studies by performing expression profiling on
the caudate and hippocampus (targets of the nigrostriatal and
mesolimbic dopaminergic systems, respectively) of the SIV
infected monkeys, treated or not with METH, using a rhesus-
specific microarray platform. Based on a p value of ,0.01 and a
fold change of greater than two, 50 genes were changed in
expression in the caudate and 49 in the hippocampus. Of these,
ten protein-coding genes were found to be significantly changed in
both, all of which were up-regulated (Table 1).
We focused on protein disulfide isomerase family member A3
(PDIA3) given its neuroprotective implications. One study
implicated a protective role for PDIA3 against neurotoxicity
induced by prion infection [16]. A similar neuroprotective role for
PDIA3 has been documented against b-amyloid aggregation in
Alzheimer’s disease [17]. Moreover, a common chord that
connects these neurodegenerative disorders is cellular stress
including generation of reactive oxygen species (ROS) and
endoplasmic reticulum (ER) stress. PDIA3 is localized in the ER
lumen and an earlier study demonstrated its induction during ER
stress [18]. Since METH has been shown to induce ER stress and
subsequent neuronal death [19], we hypothesized that PDIA3 may
be up-regulated to counter METH induced neurotoxicity.
We first validated the increase in PDIA3 in monkey striatum by
quantitative real time polymerase chain reaction, revealing a
significant increase in PDIA3 mRNA expression in the METH
treated monkeys compared to the animals not treated with METH
(Fig. 1). Since all monkeys were SIV infected, we next wanted to
assess whether METH alone is capable of inducing PDIA3. Single
dose injections of METH in mice are informative in determining
the direct effect of METH on gene expression [19,20,21]. We
therefore administered METH to mice and did a time course
experiment for striatal gene expression, examining PDIA3 and, as
a positive control, HSP5A (also known as GRP78/BiP), found by
others to be induced by METH in mice [19]. Indeed both genes
were induced by METH (Fig. 2), revealing that METH itself
induces PDIA3 in vivo.
We next performed studies on METH-treated neurons in vitro in
order to examine whether METH itself can increase the PDIA3 at
the protein level. Treatment of striatal neurons with METH
resulted in an increase in PDIA3 expression in neurons, evident in
both the soma and neuronal processes (Fig. 3). Thus not only does
METH treatment in vivo lead to increased PDIA3 expression,
METH treatment ex vivo reveals a direct distinct response in the
neurons through up-regulation of PDIA3.
To examine whether the increase in PDIA3 is neuroprotective,
we utilized SK-N-BE(2) neuroblastoma cells, chosen for their
sensitivity to METH-mediated neurotoxicity. PDIA3 was consti-
tutively expressed as well as knocked down in these cells (Fig. 4A
and B). Cytotoxicity assays revealed that knockdown of PDIA3
resulted in significantly increased METH-induced cell death
(p,0.001) compared to the PDIA3 expressing cells (Fig. 3C).
Generation of intracellular ROS is a critical contributor in
METH mediated cell death [1]. To further ascertain a potential
neuroprotective role for PDIA3, we performed an intracellular
ROS assay on these cells. A significant increase in intracellular
ROS was observed in cells knocked down for PDIA3 both in the
presence and absence of METH (p,0.001) compared to the
PDIA3 expressing cells (Fig. 5). Together, these data demonstrate
a neuroprotective role for PDIA3 during METH cytotoxicity.
Discussion
Using two groups of monkeys differing only by METH
administration, we found PDIA3, an endoplasmic reticulum
(ER) resident thiol disulfide oxidoreductase and a molecular
chaperone, to be significantly up regulated after METH
treatment. Indeed treatment of mice and of primary striatal
neurons with METH resulted in increased PDIA3 expression,
revealing its direct response to METH.
PDIA3 has been linked to numerous human disease states.
Expression of PDIA3 is increased in transformed cells, and it is
thought that the role it plays in oncogenic transformation is
directly due to its ability to control intracellular and extracellular
redox activities through its thiol-dependent reductase activity [22].
An increase in PDIA3 expression has also been observed in the
early stages of prion disease, suggesting that it may play a
neuroprotective role in the cellular response to prion infection
[16]. It has been documented that METH mediates ER stress in
the striatum [19] thus an increase in stress response proteins would
be expected. We hypothesized a similar neuroprotective effect of
PDIA3 in our current study and our cumulative data revealed a
similar neuroprotective effect of PDIA3 against METH toxicity.
The initial gene array expression profiling studies were carried
out in groups of SIV infected monkeys, differing only by the
administration of METH during the stable phase of infection. This
is in one sense a limitation of our study, in that the initial discovery
portion of the study was performed from tissue from this study.
While having uninfected animals, treated or not with METH,
would have been ideal, the use of these animals allowed an initial
discovery based approach to factors induced by METH in the
brain. Therefore we utilized mice to assess PDIA3 response to a
METH only in vivo scenario, confirming the METH-induced
PDIA3 found in the SIV infected monkeys. An additional
advantage of the initial monkey studies were its well-controlled
nature and dosing typical of human abuse was a distinct
advantage, and our subsequent studies on primary neurons and
the neuroblastoma cell line also revealed the effect on PDIA3 to be
due to METH itself.
It is possible that the up-regulation of PDIA3 could be an early
protective event preceding eventual METH mediated neurotox-
icity, similar to the increase of PDIA3 expression found early in the
course of prion disease before the extensive cell death observed in
the later stages of prion toxicity [16]. However while molecular
and imaging studies reveal a number of abnormalities in chronic
METH users, some of these are reversible with abstinence, and in
general the neuronal damage spares the cell bodies [23]. Thus
increased PDIA3 expression may be one of the mechanisms
induced to protect the neuron during METH use, enabling the cell
to attempt reparative processes during abstinence. Further in vivo
studies in model systems would allow the examination of this
possibility.
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cellular neuroprotective mechanism against a toxic drug, and
implicate PDIA3 having a role in a more general neuroprotective
pathway and as a potential target for therapeutic investigations.
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